Literature DB >> 30697584

pRNFL as a marker of disability worsening in the medium/long term in patients with MS.

Christian Cordano1, Bardia Nourbakhsh1, Michael Devereux1, Vincent Damotte1, Daniel Bennett1, Stephen L Hauser1, Bruce A C Cree1, Jeffrey M Gelfand1, Ari J Green1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30697584      PMCID: PMC6340330          DOI: 10.1212/NXI.0000000000000533

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
MS is an inflammatory and neurodegenerative disease of the CNS (including the retina) that leads to progressive neurologic disability. Disability correlates with the degree of axonal pathology in the disease.[1,2] The clinical course of MS is unpredictable, making the search for biomarkers associated with enhanced risk of disease progression a major unmet need. Spectral domain optical coherence tomography (SD-OCT) is a potential predictor of disability worsening up to 5 years of follow-up after a single evaluation of the peripapillary retinal nerve fiber layer (pRNFL).[3] Time domain OCT (TD-OCT) is an older technology, characterized by lower axial resolution and slower acquisition speed (400 axial scans per second) resulting in lower resolution images and more frequent motion artifacts compared with SD-OCT.[4] TD-OCT was used over 10 years ago to assess retinal neurodegeneration in patients with MS but only now has enough time passed to assess its actual predictive potential for clinical progression. To investigate the capacity of TD-OCT measures to predict disability worsening in patients with MS, we performed a retrospective evaluation of 305 patients with MS (228 relapsing-remitting, 29 secondary progressive, 32 clinically isolated syndrome, 10 primary progressive MS according to 2005 McDonald criteria,[5] and 6 with MS but unclear disease course) who had undergone Stratus TD-OCT (Carl Zeiss Meditec AG, Jena, Germany) from January 2006 to December 2008, collecting the values of the pRNFL and macular volume (MV). The Committee on Human Research at UCSF approved the study. All participants provided written informed consent. The baseline cohort characteristics are presented in the table. All patients had at least 1 measurement of the Expanded Disability Status Scale (EDSS) during the subsequent follow-up period. In our analyses, we used the most recent available EDSS. The median follow-up duration from the time of OCT to the most recent EDSS evaluation was 7.9 years (interquartile range 6.4–8.9 years, range 0.04–9.5 years); 91% of the cohort had >5 years of follow-up. The association between the baseline pRNFL and the subsequent EDSS was investigated using multivariable linear regression, adjusted for age and sex, taking into account the correlation of pRNFL thickness in the patient's 2 eyes (figure). For each 1-μm decrease in the pRNFL, there was a 0.024 increase in EDSS (95% CI: 0.011–0.037; p < 0.001). In a sensitivity analysis, the results were similar (0.022 increase in the EDSS, 95% CI 0.035–0.01, p = 0.001) when analyzing only patients with >5 years of follow-up. A model adjusted for the presence of previous episodes of optic neuritis yielded similar results (a 1-μm decrease in the RNFL was associated with a 0.024 increase in the EDSS; p < 0.001). There was no association with MV. The lack of consistent association of MV with disability worsening has previously been reported[3] and may relate to the lack of segmentation from whole macular thickness where some layers increase volume and others lose volume during the course of disease. In addition, TD-OCT had poorer reproducibility for volume scans because of the low speed of image acquisition. These results show that TD-OCT and a single evaluation of pRNFL atrophy is useful in predicting disability up to 6–9 years later in MS—significantly longer than has been previously reported. A limitation of the study is the absence of the baseline EDSS in the entire cohort, which limited our ability to consider its influence as a confounder in the estimate of association between the baseline RNFL and subsequent EDSS. Recent meta-analyses show that the mean RNFL loss in a population of patients with optic neuritis is similar between TD-OCT and SD-OCT.[6,7] However, despite the similarity in means at an individual level, SD-OCT is known to be more accurate. Stratus TD-OCT is no longer used in MS research because of the availability of more sophisticated OCT machines being able to quantify retinal measures with a much lower level of noise.[8] Nevertheless, despite the effect on SDs, this noise does not affect the mean, and data from earlier iterations of the technology can be useful to indicate the association between retinal thinning and future disability.
Table

Demographic and baseline characteristics and the follow-up data of the study population (number of patients = 305)

Figure

Association of baseline RNFL with EDSS at the end of the follow-up period

RNFL = retinal nerve fiber layer.

Demographic and baseline characteristics and the follow-up data of the study population (number of patients = 305)

Association of baseline RNFL with EDSS at the end of the follow-up period

RNFL = retinal nerve fiber layer.
  8 in total

Review 1.  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

Authors:  Axel Petzold; Johannes F de Boer; Sven Schippling; Patrik Vermersch; Randy Kardon; Ari Green; Peter A Calabresi; Chris Polman
Journal:  Lancet Neurol       Date:  2010-09       Impact factor: 44.182

Review 2.  Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis.

Authors:  Elliot M Frohman; Fiona Costello; Olaf Stüve; Peter Calabresi; David H Miller; Simon J Hickman; Robert Sergott; Amy Conger; Amber Salter; Kimberly H Krumwiede; Teresa C Frohman; Laura Balcer; Robert Zivadinov
Journal:  Arch Neurol       Date:  2008-01

3.  Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Authors:  Elena H Martinez-Lapiscina; Sam Arnow; James A Wilson; Shiv Saidha; Jana Lizrova Preiningerova; Timm Oberwahrenbrock; Alexander U Brandt; Luis E Pablo; Simone Guerrieri; Ines Gonzalez; Olivier Outteryck; Ann-Kristin Mueller; Phillip Albrecht; Wesley Chan; Sebastian Lukas; Lisanne J Balk; Clare Fraser; Jette L Frederiksen; Jennifer Resto; Teresa Frohman; Christian Cordano; Irati Zubizarreta; Magi Andorra; Bernardo Sanchez-Dalmau; Albert Saiz; Robert Bermel; Alexander Klistorner; Axel Petzold; Sven Schippling; Fiona Costello; Orhan Aktas; Patrick Vermersch; Celia Oreja-Guevara; Giancarlo Comi; Letizia Leocani; Elena Garcia-Martin; Friedemann Paul; Eva Havrdova; Elliot Frohman; Laura J Balcer; Ari J Green; Peter A Calabresi; Pablo Villoslada
Journal:  Lancet Neurol       Date:  2016-03-18       Impact factor: 44.182

Review 4.  Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Authors:  Axel Petzold; Laura J Balcer; Peter A Calabresi; Fiona Costello; Teresa C Frohman; Elliot M Frohman; Elena H Martinez-Lapiscina; Ari J Green; Randy Kardon; Olivier Outteryck; Friedemann Paul; Sven Schippling; Patrik Vermersch; Pablo Villoslada; Lisanne J Balk
Journal:  Lancet Neurol       Date:  2017-09-12       Impact factor: 44.182

5.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease.

Authors:  D L Arnold; P M Matthews; G Francis; J Antel
Journal:  Magn Reson Med       Date:  1990-04       Impact factor: 4.668

6.  Evaluation of retinal nerve fiber layer progression in glaucoma: a comparison between spectral-domain and time-domain optical coherence tomography.

Authors:  Christopher Kai-Shun Leung; Vivian Chiu; Robert N Weinreb; Shu Liu; Cong Ye; Marco Yu; Carol Yim-Lui Cheung; Gilda Lai; Dennis Shun-Chiu Lam
Journal:  Ophthalmology       Date:  2011-04-29       Impact factor: 12.079

Review 7.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

8.  The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials.

Authors:  Christina V Warner; Stephanie B Syc; Aleksandra M Stankiewicz; Girish Hiremath; Sheena K Farrell; Ciprian M Crainiceanu; Amy Conger; Teresa C Frohman; Esther R Bisker; Laura J Balcer; Elliot M Frohman; Peter A Calabresi; Shiv Saidha
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

  8 in total
  6 in total

1.  Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.

Authors:  Christian Cordano; Bardia Nourbakhsh; Hao H Yiu; Nico Papinutto; Eduardo Caverzasi; Ahmed Abdelhak; Frederike C Oertel; Alexandra Beaudry-Richard; Adam Santaniello; Simone Sacco; Daniel J Bennett; Apraham Gomez; Christina J Sigurdson; Stephen L Hauser; Roberta Magliozzi; Bruce A C Cree; Roland G Henry; Ari J Green
Journal:  Neurology       Date:  2022-08-29       Impact factor: 11.800

2.  Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study.

Authors:  Alessandro Masala; Ilaria Di Mola; Maria Cellerino; Valentina Pera; Aldo Vagge; Antonio Uccelli; Cordano Christian; Carlo E Traverso; Michele Iester
Journal:  J Clin Neurol       Date:  2022-05       Impact factor: 2.566

3.  Silent progression in disease activity-free relapsing multiple sclerosis.

Authors:  Bruce A C Cree; Jill A Hollenbach; Riley Bove; Gina Kirkish; Simone Sacco; Eduardo Caverzasi; Antje Bischof; Tristan Gundel; Alyssa H Zhu; Nico Papinutto; William A Stern; Carolyn Bevan; Andrew Romeo; Douglas S Goodin; Jeffrey M Gelfand; Jennifer Graves; Ari J Green; Michael R Wilson; Scott S Zamvil; Chao Zhao; Refujia Gomez; Nicholas R Ragan; Gillian Q Rush; Patrick Barba; Adam Santaniello; Sergio E Baranzini; Jorge R Oksenberg; Roland G Henry; Stephen L Hauser
Journal:  Ann Neurol       Date:  2019-03-30       Impact factor: 10.422

4.  Failed remyelination of the nonhuman primate optic nerve leads to axon degeneration, retinal damages, and visual dysfunction.

Authors:  Nadège Sarrazin; Estelle Chavret-Reculon; Corinne Bachelin; Mehdi Felfli; Rafik Arab; Sophie Gilardeau; Elena Brazhnikova; Elisabeth Dubus; Lydia Yaha-Cherif; Jean Lorenceau; Serge Picaud; Serge Rosolen; Pierre Moissonnier; Pierre Pouget; Anne Baron-Van Evercooren
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-02       Impact factor: 12.779

5.  N2 year in review.

Authors:  Josep Dalmau; Marinos C Dalakas; Dennis L Kolson; Friedemann Paul; Scott S Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-12

Review 6.  Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis.

Authors:  Arshad Mehmood; Wajid Ali; Shuang Song; Zaheer Ud Din; Ruo-Yi Guo; Wahid Shah; Ikram Ilahi; Bowen Yin; Hongjing Yan; Lu Zhang; Murad Khan; Wajid Ali; Liaqat Zeb; Hamidreza Safari; Bin Li
Journal:  Brain Behav       Date:  2021-09-14       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.